Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy

Richard L Piekarz; Dan L Sackett; Susan E Bates

doi:10.1097/PPO.0b013e31803c73cc

Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy

Cancer J. 2007 Jan-Feb;13(1):30-9. doi: 10.1097/PPO.0b013e31803c73cc.

Authors

Richard L Piekarz¹, Dan L Sackett, Susan E Bates

Affiliation

¹ Molecular Therapeutic Section, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1903, USA. rpiekarz@nih.gov

PMID: 17464244
DOI: 10.1097/PPO.0b013e31803c73cc

Abstract

The histone deacetylase inhibitors are a new class of agents that are currently in various stages of clinical development. Clinical trials have demonstrated activity, urging further investigation. At the same time, it has been discovered that these agents have their own challenges. In this review, we discuss clinical data gathered to date, combination therapies designed to increase efficacy, and toxicities attributed to this new class of agents.

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Clinical Trials as Topic
Enzyme Inhibitors / adverse effects
Enzyme Inhibitors / chemistry
Enzyme Inhibitors / therapeutic use*
Histone Deacetylase Inhibitors*
Histone Deacetylases / chemistry
Humans

Substances

Antineoplastic Agents
Enzyme Inhibitors
Histone Deacetylase Inhibitors
Histone Deacetylases